Kymera Therapeutics
NASDAQ: KYMRFounded 2016 · Incorporated in Delaware · 303 employees on LinkedIn · 10 known investors
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
Founders & leadership
Kymera Therapeutics was founded in 2016 by Nello Mainolfi.
NM
Nello MainolfiinFounder, President and Chief Executive OfficerFounder of Kymera Therapeutics, a clinical-stage biotech developing targeted protein degradation medicines, where he works on advancing a new class of degrader therapies. He has held science, leadership, and business roles across large pharma and biotech, with experience in company creation, scaling, strategic partnerships, and private and public offerings.
Investors · 10
Atlas VentureCambridge · $500K – $1M
Avoro Capital AdvisorsNew York
Bain Capital Life SciencesBoston
Bessemer Venture PartnersRedwood City · $5M – $100M
Hatteras Venture PartnersResearch Triangle · $500K – $4M
MRL Ventures FundCambridge · $25M
Nextech InvestZurich · $648K – $3.2M
Pfizer Venture Investments$5M – $20M
Sanofi VenturesCambridge · $5M
Solasta VenturesBoston
Founder mafia
2 people who came through Kymera Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBioworld63 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha47 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Kymera Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Kymera Therapeutics do?
- Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
- Who founded Kymera Therapeutics?
- Kymera Therapeutics was founded by Nello Mainolfi in 2016.
- Who are Kymera Therapeutics's investors?
- Kymera Therapeutics's investors include Atlas Venture, Avoro Capital Advisors, Bain Capital Life Sciences, Bessemer Venture Partners, Hatteras Venture Partners, MRL Ventures Fund, Nextech Invest, Pfizer Venture Investments and 2 more.